Correlation Between Oryzon Genomics and Pharma Mar

Can any of the company-specific risk be diversified away by investing in both Oryzon Genomics and Pharma Mar at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oryzon Genomics and Pharma Mar into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oryzon Genomics SA and Pharma Mar SA, you can compare the effects of market volatilities on Oryzon Genomics and Pharma Mar and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oryzon Genomics with a short position of Pharma Mar. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oryzon Genomics and Pharma Mar.

Diversification Opportunities for Oryzon Genomics and Pharma Mar

-0.01

Correlation Coefficient

Oryzon Genomics  Pharma Mar

Good diversification

The 3 months correlation between Oryzon and Pharma is -0.01. Overlapping area represents the amount of risk that can be diversified away by holding Oryzon Genomics SA and Pharma Mar SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pharma Mar SA and Oryzon Genomics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oryzon Genomics SA are associated (or correlated) with Pharma Mar. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pharma Mar SA has no effect on the direction of Oryzon Genomics i.e., Oryzon Genomics and Pharma Mar go up and down completely randomly.

Pair Corralation between Oryzon Genomics and Pharma Mar

Assuming the 90 days trading horizon Oryzon Genomics SA is expected to under-perform the Pharma Mar. In addition to that, Oryzon Genomics is 1.71 times more volatile than Pharma Mar SA. It trades about -0.1 of its total potential returns per unit of risk. Pharma Mar SA is currently generating about 0.31 per unit of volatility. If you would invest  2,796  in Pharma Mar SA on February 5, 2024 and sell it today you would earn a total of  318.00  from holding Pharma Mar SA or generate 11.37% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Oryzon Genomics SA  vs.  Pharma Mar SA

Oryzon Genomics SA

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Oryzon Genomics SA are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound basic indicators, Oryzon Genomics is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders.

Pharma Mar SA

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Pharma Mar SA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in June 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Oryzon Genomics and Pharma Mar

The main advantage of trading using opposite Oryzon Genomics and Pharma Mar positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oryzon Genomics position performs unexpectedly, Pharma Mar can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharma Mar will offset losses from the drop in Pharma Mar's long position.

The idea behind Oryzon Genomics SA and Pharma Mar SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.